359 related articles for article (PubMed ID: 27561848)
1. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
Kubeček O; Soukup T; Paulík A; Kopecký J
BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
[TBL] [Abstract][Full Text] [Related]
2. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
[TBL] [Abstract][Full Text] [Related]
3. NanoString technology distinguishes anti-TIF-1γ
Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
[TBL] [Abstract][Full Text] [Related]
4. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
[TBL] [Abstract][Full Text] [Related]
5. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
[TBL] [Abstract][Full Text] [Related]
6. Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor.
Zhang H; Yue J; Hou X; Lu H; Bikdeli A; Guo H; Li H; Li D
BMC Pulm Med; 2023 Jul; 23(1):248. PubMed ID: 37415133
[TBL] [Abstract][Full Text] [Related]
7. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
Front Immunol; 2020; 11():625896. PubMed ID: 33613568
[TBL] [Abstract][Full Text] [Related]
8. Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis.
Kato T; Ito S; Tsuzuki T; Watanabe D; Kubo A; Yamaguchi E
Respirol Case Rep; 2019 May; 7(4):e00412. PubMed ID: 30906559
[TBL] [Abstract][Full Text] [Related]
9. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
10. Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study.
Vázquez-Del Mercado M; Martínez-García EA; Daneri-Navarro A; Gómez-Bañuelos E; Martín-Márquez BT; Pizano-Martínez O; Wilson-Manríquez EA; Corona-Sánchez EG; Chavarria-Avila E; Sandoval-García F; Satoh M
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):328-333. PubMed ID: 33876712
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
[TBL] [Abstract][Full Text] [Related]
12. Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.
Mugii N; Hasegawa M; Matsushita T; Hamaguchi Y; Oohata S; Okita H; Yahata T; Someya F; Inoue K; Murono S; Fujimoto M; Takehara K
PLoS One; 2016; 11(5):e0154746. PubMed ID: 27167831
[TBL] [Abstract][Full Text] [Related]
13. Remarkable remission of symptomatic dermatomyositis after curative breast cancer surgery.
Fujino M; Kawashima M; Yoshifuji H; Nakashima R; Yamada Y; Matsumoto Y; Kawaguchi-Sakita N; Mori Y; Pu F; Yamaguchi A; Kawaguchi K; Takada M; Toi M
Int Cancer Conf J; 2024 Apr; 13(2):111-118. PubMed ID: 38524641
[TBL] [Abstract][Full Text] [Related]
14. Anti-transcription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer.
Teraishi M; Nakajima K; Ishimoto T; Yamamoto M; Maeda N; Muro Y; Sano S
Int J Rheum Dis; 2018 Apr; 21(4):900-902. PubMed ID: 29341447
[No Abstract] [Full Text] [Related]
15. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
16. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.
Kang EH; Kuwana M; Okazaki Y; Lee EY; Lee YJ; Lee EB; Song YW
Mod Rheumatol; 2014 Nov; 24(6):945-8. PubMed ID: 24670134
[TBL] [Abstract][Full Text] [Related]
17. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature.
Zarkavelis G; Mauri D; Karassa F; Eleftherios K; Pentheroudakis G; Pappadaki A; Mavroeidis L; Ntellas P; Gkoura S; Gazouli I
Contemp Oncol (Pozn); 2020; 24(1):75-78. PubMed ID: 32514241
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy.
Harada Y; Tominaga M; Iitoh E; Kaieda S; Koga T; Fujimoto K; Chikasue T; Obara H; Kakuma T; Ida H; Kawayama T; Hoshino T
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407533
[TBL] [Abstract][Full Text] [Related]
19. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
20. Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis.
Zhang S; Chen YL; Liu CL; Xie JY; Sun BD; Liu DZ
Front Immunol; 2022; 13():757802. PubMed ID: 35185871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
